Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott launches updated stroke device

This article was originally published in The Gray Sheet

Executive Summary

Firm announces CE mark approval and European launch of its Emboshield PRO embolic protection system on Sept. 13. The next-generation device is more radiopaque than its predecessor, providing better X-ray visibility, Abbott says. Its small size and enhanced profile position the device as a new option for tortuous vessels, according to the firm. Separately, on Sept. 12 the firm reported an expansion of its manufacturing facility in Ireland to ramp up production of the Xience V drug-eluting stent, expected to debut in October (1"The Gray Sheet" Sept. 11, 2006, p. 5)...

You may also be interested in...

On Eve Of European Launch, Abbott’s Xience V Outperforms Taxus

Abbott is trumpeting the latest findings about its Xience V drug-eluting stent in preparation for next month's European launch

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts